{"id":5683,"date":"2024-01-17T11:06:37","date_gmt":"2024-01-17T16:06:37","guid":{"rendered":"https:\/\/neoaptamers.com\/?p=5683"},"modified":"2026-04-08T13:57:42","modified_gmt":"2026-04-08T17:57:42","slug":"the-power-of-aptamarkers-a-new-frontier-in-disease-management","status":"publish","type":"post","link":"https:\/\/neoaptamers.com\/fr\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\/","title":{"rendered":"The Power of Aptamarkers: A New Frontier in Disease Management"},"content":{"rendered":"<ul>\n<li><strong>La d\u00e9couverte r\u00e9volutionnaire de biomarqueurs :<\/strong> Aptamarker permet un d\u00e9pistage agnostique des biomarqueurs, transformant la compr\u00e9hension des maladies. Il permet la stratification des patients dans les essais cliniques pour une s\u00e9curit\u00e9 accrue et une m\u00e9decine de pr\u00e9cision.<\/li>\n<li><strong>Le d\u00e9veloppement de m\u00e9dicaments pr\u00e9dictifs et pr\u00e9cis.<\/strong> Pr\u00e9dit les effets secondaires et traduit les r\u00e9sultats des mod\u00e8les animaux pour un d\u00e9veloppement plus s\u00fbr des m\u00e9dicaments. Cartographie les sites de liaison des m\u00e9dicaments et d\u00e9veloppe des tests dynamiques pour des effets th\u00e9rapeutiques optimaux.<\/li>\n<li><strong>Analyse prot\u00e9omique compl\u00e8te :<\/strong> Remplace la prot\u00e9omique, en analysant simultan\u00e9ment toutes les prot\u00e9ines pour une d\u00e9couverte efficace de biomarqueurs. Acc\u00e9l\u00e8re la recherche, offrant une vue globale sur diverses maladies et conditions.<\/li>\n<\/ul>\n<p>Dans le domaine de la recherche m\u00e9dicale et de la biotechnologie, les innovations r\u00e9volutionnaires peuvent remodeler le paysage des soins de sant\u00e9. La plateforme Aptamarker de NeoVentures Biotechnology se trouve \u00e0 l'avant-garde de ces innovations, remettant en question les normes traditionnelles de d\u00e9couverte de biomarqueurs et ouvrant une nouvelle \u00e8re dans la gestion des maladies. Ce blog explore les applications multifacettes des Aptamarkers et comment ils r\u00e9volutionnent notre approche pour comprendre, diagnostiquer et traiter les maladies.<\/p>\n<ol>\n<li><u> Biomarqueurs dans les biofluides pour n'importe quelle maladie : D\u00e9pistage agnostique avec la capacit\u00e9 de caract\u00e9riser les cibles des biomarqueurs<\/u><\/li>\n<\/ol>\n<h3>D\u00e9pistage agnostique :<\/h3>\n<p>La capacit\u00e9 unique d'Aptamarker \u00e0 effectuer un d\u00e9pistage agnostique repr\u00e9sente un changement de paradigme dans la d\u00e9couverte des biomarqueurs. Contrairement aux m\u00e9thodes traditionnelles qui n\u00e9cessitent une compr\u00e9hension approfondie des intrications mol\u00e9culaires de la maladie, Aptamarker permet aux chercheurs d'identifier des biomarqueurs dans les biofluides sans connaissance pr\u00e9alable de l'\u00e9tiologie de la maladie. Cela est particuli\u00e8rement pr\u00e9cieux dans les situations o\u00f9 les maladies sont mal comprises ou lorsqu'il s'agit de menaces sanitaires \u00e9mergentes.<\/p>\n<h3>Caract\u00e9risation des Cibles :<\/h3>\n<p>D\u00e9passant la simple identification des biomarqueurs, Aptamarker offre des informations sur les caract\u00e9ristiques et les cibles de ces biomarqueurs. Cette profondeur de compr\u00e9hension change la donne, offrant aux chercheurs une feuille de route pour d\u00e9voiler les voies biologiques impliqu\u00e9es. Cette connaissance aide non seulement \u00e0 d\u00e9velopper des diagnostics plus efficaces, mais ouvre \u00e9galement des perspectives pour la d\u00e9couverte de nouvelles cibles th\u00e9rapeutiques.<\/p>\n<ol start=\"2\">\n<li><u> Stratification des Patients : Crit\u00e8res d'Exclusion et d'Inclusion<\/u><\/li>\n<\/ol>\n<h3>Exclusion (Identification des Patients Pr\u00e9dispos\u00e9s aux Effets Secondaires ou \u00e0 l'Absence de R\u00e9ponse)<\/h3>\n<p>L'une des applications r\u00e9volutionnaires des Aptamarkers r\u00e9side dans la stratification des patients. En identifiant rapidement les biomarqueurs associ\u00e9s \u00e0 des r\u00e9actions ind\u00e9sirables ou \u00e0 une absence de r\u00e9ponse, les Aptamarkers permettent l'exclusion des individus pr\u00e9dispos\u00e9s aux effets secondaires. Cela am\u00e9liore non seulement la s\u00e9curit\u00e9 des patients, mais simplifie \u00e9galement les essais cliniques en excluant les candidats moins susceptibles de b\u00e9n\u00e9ficier d'un traitement particulier.<\/p>\n<h3>Inclusion (Inscription de patients pr\u00e9dispos\u00e9s \u00e0 la r\u00e9ponse au traitement):<\/h3>\n<p>\u00c0 l'inverse, Aptamarker facilite l'inclusion de patients pr\u00e9sentant une pr\u00e9disposition \u00e0 une r\u00e9ponse positive au traitement. Cette approche personnalis\u00e9e am\u00e9liore l'efficacit\u00e9 des essais cliniques, garantissant que les personnes inscrites sont plus susceptibles de b\u00e9n\u00e9ficier de la th\u00e9rapie en cours d'investigation. Cette strat\u00e9gie sur mesure est une \u00e9tape essentielle vers l'avancement de la m\u00e9decine de pr\u00e9cision.<\/p>\n<ol start=\"3\">\n<li><u> Pr\u00e9diction de la R\u00e9ponse aux Effets Secondaires\/Traduction depuis les Mod\u00e8les Anim\u00e9s<\/u><\/li>\n<\/ol>\n<h3>Pr\u00e9diction de la R\u00e9ponse aux Effets Secondaires<\/h3>\n<p>L'analyse compl\u00e8te d'Aptamarker joue un r\u00f4le essentiel dans la pr\u00e9diction des effets secondaires en identifiant les biomarqueurs associ\u00e9s aux r\u00e9actions ind\u00e9sirables. Cette pr\u00e9voyance donne aux chercheurs et aux cliniciens la capacit\u00e9 d'anticiper et de g\u00e9rer plus efficacement les effets secondaires, contribuant ainsi au d\u00e9veloppement plus s\u00fbr des m\u00e9dicaments et \u00e0 leur utilisation clinique.<\/p>\n<h3>Traduction \u00e0 partir des mod\u00e8les animaux :<\/h3>\n<p>De plus, Aptamarker contribue \u00e0 la traduction des d\u00e9couvertes \u00e0 partir des mod\u00e8les animaux vers les applications humaines. En identifiant les biomarqueurs associ\u00e9s \u00e0 la toxicit\u00e9 hors cible dans les \u00e9tudes pr\u00e9cliniques, les chercheurs peuvent mieux extrapoler ces r\u00e9sultats pour pr\u00e9dire et att\u00e9nuer les \u00e9ventuelles toxicit\u00e9s chez les sujets humains, am\u00e9liorant ainsi la fiabilit\u00e9 des pipelines de d\u00e9veloppement de m\u00e9dicaments.<\/p>\n<ol start=\"4\">\n<li><u> Caract\u00e9risation de l'Engagement de la Cible : Cartographie des Sites de Liaison des M\u00e9dicaments \/ D\u00e9veloppement de Tests Dynamiques pour les Taux d'Activation et de D\u00e9sactivation.<\/u><\/li>\n<\/ol>\n<h3>Cartographie des Sites de Liaison des M\u00e9dicaments :<\/h3>\n<p>La pr\u00e9cision d'Aptamarker s'\u00e9tend \u00e0 la cartographie des sites de liaison des m\u00e9dicaments sur les biomol\u00e9cules. Cette information est cruciale pour la conception de m\u00e9dicaments avec une sp\u00e9cificit\u00e9 et une efficacit\u00e9 accrues, minimisant les effets hors cible et optimisant les interventions th\u00e9rapeutiques.<\/p>\n<h3>Tests dynamiques pour les taux d'activation\/d\u00e9sactivation :<\/h3>\n<p>De plus, la capacit\u00e9 d'Aptamarker \u00e0 d\u00e9velopper des tests dynamiques pour les taux d'activation\/d\u00e9sactivation de la liaison m\u00e9dicamenteuse offre une compr\u00e9hension plus approfondie de la cin\u00e9tique des interactions m\u00e9dicament-cible. Cette connaissance est cruciale pour ajuster finement les doses et les sch\u00e9mas posologiques des m\u00e9dicaments, garantissant des effets th\u00e9rapeutiques optimaux tout en minimisant les effets secondaires potentiels, un aspect crucial de la m\u00e9decine personnalis\u00e9e.<\/p>\n<ol start=\"5\">\n<li><u> Remplacer la prot\u00e9omique : Toutes les prot\u00e9ines et complexes \u00e0 la fois<\/u><\/li>\n<\/ol>\n<h3>Analyse compl\u00e8te :<\/h3>\n<p>Peut-\u00eatre l'un des aspects les plus impactants d'Aptamarker est sa capacit\u00e9 \u00e0 remplacer la prot\u00e9omique, permettant l'analyse simultan\u00e9e de toutes les prot\u00e9ines et complexes pr\u00e9sents dans un \u00e9chantillon biologique. Cette approche globale offre une vision holistique du paysage mol\u00e9culaire, fournissant une multitude d'informations aux chercheurs pour explorer les m\u00e9canismes de la maladie et identifier des cibles th\u00e9rapeutiques potentielles.<\/p>\n<h3>L'efficacit\u00e9 en termes de temps et de ressources :<\/h3>\n<p>Le processus rationalis\u00e9 d'analyse de l'ensemble des prot\u00e9ines en une seule fois r\u00e9duit le temps et les ressources n\u00e9cessaires \u00e0 la d\u00e9couverte de biomarqueurs. Cette efficacit\u00e9 acc\u00e9l\u00e8re non seulement le processus de recherche, mais ouvre \u00e9galement des voies pour \u00e9tudier un \u00e9ventail plus large de maladies et de conditions, potentiellement en d\u00e9couvrant de nouvelles connexions et informations.<\/p>\n<p>La plateforme Aptamarker de NeoVentures Biotechnology repr\u00e9sente un bond en avant consid\u00e9rable dans le domaine de la d\u00e9couverte et de l'application des biomarqueurs. En offrant un ensemble d'outils polyvalents aux chercheurs et aux cliniciens, les Aptamarkers sont pr\u00eats \u00e0 faire avancer la m\u00e9decine personnalis\u00e9e, \u00e0 am\u00e9liorer les r\u00e9sultats des patients et \u00e0 optimiser les processus de d\u00e9veloppement de m\u00e9dicaments. \u00c0 mesure que nous explorons davantage le potentiel des Aptamarkers, nous ouvrons la voie \u00e0 un avenir o\u00f9 les maladies pourront \u00eatre comprises et g\u00e9r\u00e9es avec une pr\u00e9cision et une efficacit\u00e9 sans pr\u00e9c\u00e9dent. L'\u00e8re des Aptamarkers a commenc\u00e9, promettant une nouvelle fronti\u00e8re dans la qu\u00eate d'une meilleure sant\u00e9 et d'un bien-\u00eatre accru.<\/p>","protected":false},"excerpt":{"rendered":"<p>Revolutionary Biomarker Discovery: Aptamarker allows agnostic screening for biomarkers, transforming disease understanding. Enables patient stratification in clinical trials for enhanced safety and precision medicine. Predictive and Precise Drug Development: Predicts side effects and translates animal model findings for safer drug development. Maps drug binding sites and develops dynamic tests for optimal therapeutic effects. Comprehensive Proteomic&hellip;&nbsp;<a href=\"https:\/\/neoaptamers.com\/fr\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\/\" rel=\"bookmark\">Lire la suite &raquo;<span class=\"screen-reader-text\">The Power of Aptamarkers: A New Frontier in Disease Management<\/span><\/a><\/p>","protected":false},"author":2,"featured_media":4778,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"off","neve_meta_content_width":70,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[8],"tags":[],"class_list":["post-5683","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aptamers"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The Power of Aptamarkers: A New Frontier in Disease Management<\/title>\n<meta name=\"description\" content=\"Explore the multifaceted applications of Aptamarkers and how they are revolutionizing our approach to disease management.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/neoaptamers.com\/fr\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Power of Aptamarkers: A New Frontier in Disease Management\" \/>\n<meta property=\"og:description\" content=\"Explore the multifaceted applications of Aptamarkers and how they are revolutionizing our approach to disease management.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/neoaptamers.com\/fr\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\/\" \/>\n<meta property=\"og:site_name\" content=\"neoaptamers\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-17T16:06:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-08T17:57:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/08\/julia-koblitz-RlOAwXt2fEA-unsplash-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1606\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Gregory Penner\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Gregory Penner\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\\\/\"},\"author\":{\"name\":\"Gregory Penner\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/person\\\/641d6a3e016e13414b8d0d0ffd5847ad\"},\"headline\":\"The Power of Aptamarkers: A New Frontier in Disease Management\",\"datePublished\":\"2024-01-17T16:06:37+00:00\",\"dateModified\":\"2026-04-08T17:57:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\\\/\"},\"wordCount\":831,\"publisher\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/julia-koblitz-RlOAwXt2fEA-unsplash-scaled.jpg\",\"articleSection\":[\"Aptamers\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\\\/\",\"name\":\"The Power of Aptamarkers: A New Frontier in Disease Management\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/julia-koblitz-RlOAwXt2fEA-unsplash-scaled.jpg\",\"datePublished\":\"2024-01-17T16:06:37+00:00\",\"dateModified\":\"2026-04-08T17:57:42+00:00\",\"description\":\"Explore the multifaceted applications of Aptamarkers and how they are revolutionizing our approach to disease management.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/neoaptamers.com\\\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\\\/#primaryimage\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/julia-koblitz-RlOAwXt2fEA-unsplash-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/julia-koblitz-RlOAwXt2fEA-unsplash-scaled.jpg\",\"width\":2560,\"height\":1606,\"caption\":\"Female scientist in a laboratory carefully dispensing liquid into test tubes.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neoaptamers.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Power of Aptamarkers: A New Frontier in Disease Management\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"name\":\"Neoaptamers.com\",\"description\":\"Neoventures Biotechnology Inc.\",\"publisher\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/neoaptamers.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\",\"name\":\"NeoVentures Biotechnology Inc.\",\"alternateName\":\"NVB\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"contentUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"width\":500,\"height\":500,\"caption\":\"NeoVentures Biotechnology Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/neoventures-biotechnology-inc-\\\/\",\"https:\\\/\\\/www.reddit.com\\\/user\\\/NeoVenturesBiotech\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@neoaptamers7964\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/person\\\/641d6a3e016e13414b8d0d0ffd5847ad\",\"name\":\"Gregory Penner\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"caption\":\"Gregory Penner\"},\"description\":\"Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. \u00a0He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases. Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures. Click here to get in touch with our team.\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Power of Aptamarkers: A New Frontier in Disease Management","description":"Explore the multifaceted applications of Aptamarkers and how they are revolutionizing our approach to disease management.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/neoaptamers.com\/fr\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\/","og_locale":"fr_FR","og_type":"article","og_title":"The Power of Aptamarkers: A New Frontier in Disease Management","og_description":"Explore the multifaceted applications of Aptamarkers and how they are revolutionizing our approach to disease management.","og_url":"https:\/\/neoaptamers.com\/fr\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\/","og_site_name":"neoaptamers","article_published_time":"2024-01-17T16:06:37+00:00","article_modified_time":"2026-04-08T17:57:42+00:00","og_image":[{"width":2560,"height":1606,"url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/08\/julia-koblitz-RlOAwXt2fEA-unsplash-scaled.jpg","type":"image\/jpeg"}],"author":"Gregory Penner","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Gregory Penner","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/neoaptamers.com\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\/#article","isPartOf":{"@id":"https:\/\/neoaptamers.com\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\/"},"author":{"name":"Gregory Penner","@id":"https:\/\/neoaptamers.com\/#\/schema\/person\/641d6a3e016e13414b8d0d0ffd5847ad"},"headline":"The Power of Aptamarkers: A New Frontier in Disease Management","datePublished":"2024-01-17T16:06:37+00:00","dateModified":"2026-04-08T17:57:42+00:00","mainEntityOfPage":{"@id":"https:\/\/neoaptamers.com\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\/"},"wordCount":831,"publisher":{"@id":"https:\/\/neoaptamers.com\/#organization"},"image":{"@id":"https:\/\/neoaptamers.com\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\/#primaryimage"},"thumbnailUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/08\/julia-koblitz-RlOAwXt2fEA-unsplash-scaled.jpg","articleSection":["Aptamers"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/neoaptamers.com\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\/","url":"https:\/\/neoaptamers.com\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\/","name":"The Power of Aptamarkers: A New Frontier in Disease Management","isPartOf":{"@id":"https:\/\/neoaptamers.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/neoaptamers.com\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\/#primaryimage"},"image":{"@id":"https:\/\/neoaptamers.com\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\/#primaryimage"},"thumbnailUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/08\/julia-koblitz-RlOAwXt2fEA-unsplash-scaled.jpg","datePublished":"2024-01-17T16:06:37+00:00","dateModified":"2026-04-08T17:57:42+00:00","description":"Explore the multifaceted applications of Aptamarkers and how they are revolutionizing our approach to disease management.","breadcrumb":{"@id":"https:\/\/neoaptamers.com\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/neoaptamers.com\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/neoaptamers.com\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\/#primaryimage","url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/08\/julia-koblitz-RlOAwXt2fEA-unsplash-scaled.jpg","contentUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/08\/julia-koblitz-RlOAwXt2fEA-unsplash-scaled.jpg","width":2560,"height":1606,"caption":"Female scientist in a laboratory carefully dispensing liquid into test tubes."},{"@type":"BreadcrumbList","@id":"https:\/\/neoaptamers.com\/the-power-of-aptamarkers-a-new-frontier-in-disease-management\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/neoaptamers.com\/"},{"@type":"ListItem","position":2,"name":"The Power of Aptamarkers: A New Frontier in Disease Management"}]},{"@type":"WebSite","@id":"https:\/\/neoaptamers.com\/#website","url":"https:\/\/neoaptamers.com\/","name":"Neoaptamers.com","description":"Neoventures Biotechnology Inc.","publisher":{"@id":"https:\/\/neoaptamers.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/neoaptamers.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/neoaptamers.com\/#organization","name":"NeoVentures Biotechnology Inc.","alternateName":"NVB","url":"https:\/\/neoaptamers.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/","url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","contentUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","width":500,"height":500,"caption":"NeoVentures Biotechnology Inc."},"image":{"@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/neoventures-biotechnology-inc-\/","https:\/\/www.reddit.com\/user\/NeoVenturesBiotech\/","https:\/\/www.youtube.com\/@neoaptamers7964"]},{"@type":"Person","@id":"https:\/\/neoaptamers.com\/#\/schema\/person\/641d6a3e016e13414b8d0d0ffd5847ad","name":"Gregory Penner","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","caption":"Gregory Penner"},"description":"Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. \u00a0He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases. Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures. Click here to get in touch with our team."}]}},"_links":{"self":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/posts\/5683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/comments?post=5683"}],"version-history":[{"count":3,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/posts\/5683\/revisions"}],"predecessor-version":[{"id":6474,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/posts\/5683\/revisions\/6474"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/media\/4778"}],"wp:attachment":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/media?parent=5683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/categories?post=5683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/tags?post=5683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}